Navigation Links
Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
Date:2/11/2010

NANJING, China, Feb. 11 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that one of its subsidiaries, Nanjing Simcere Dongyuan Pharmaceutical Co. Ltd., has received new drug registration approval from the State Food and Drug Administration ("SFDA") to manufacture and sell Zanamivir, a neuraminidase inhibitor inhalant used in the prevention and treatment of Influenza A and Influenza B. Zanamivir is marketed globally by GlaxoSmithKline under the trade name Relenza.

Zanamivir is one of only two WHO approved drugs to which the new H1N1 strain of influenza A has been shown to be susceptible. GlaxoSmithKline granted a license to Simcere in 2006 to manufacture and sell Zanamivir and its formulations in China. Simcere is the only pharmaceutical company in mainland China that has such a license.

Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group, commented, "We are delighted to receive SFDA approval to manufacture and sell Zanamivir, which has proved very successful in the fight against the H1N1 strain of Influenza A. With our leading domestic manufacturing facilities, well-known brand and nationwide marketing platform, Simcere is well prepared to bring this exciting drug to China."

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group ( SCR, Simcere) is
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
2. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
3. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
4. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
5. Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
10. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
11. CryoCor Receives FDA Approval for Right Atrial Flutter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  Decision Resources Group ... infectious disease (ID) specialists are willing to prescribe ... (oritavancin) for use as OPAT, approximately two-thirds of ... agents to their hospital inpatients. However, our findings ... patients are initiated on OPAT following hospital discharge, ...
(Date:7/10/2014)... Decision Resources Group finds that over half ... and Drug Administration,s (FDA) approval of Vifor Fresenius Medical ... approved by the FDA in November 2013 for the ... on dialysis. Other key findings from the ... : , Bundling: ...
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... Varian Medical Systems (NYSE: VAR ) ... U.S. Customs and Border Protection (CBP) for multiple IntellX® cargo ... company,s largest single order for Varian,s IntellX gantry systems. The ... vehicles for both border security and manifest verification purposes. ...
... 2011 DURECT Corporation (Nasdaq: DRRX ) ... (FDA) has accepted the resubmission of the New Drug ... KG ) and the PDUFA goal date ... ) REMOXY, based on DURECT,s ORADUR® technology, ...
Cached Medicine Technology:Varian Medical Systems' Security and Inspection Products Group Receives Largest Single Order for IntellX Systems 2REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 2REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 3
(Date:7/11/2014)... reports that tickets to the Argentina vs. Germany World ... Brazil and Netherlands are in high demand. The ... at Estadio Nacional de Brasilia Mane Garrincha Brasila, Federal District. ... 13th at Estadio Jornalista Mario Filho - Estadio do Maracana, ... are guaranteed to be authentic and are covered by Ticket ...
(Date:7/11/2014)... 11, 2014 Butler Mobility has recently updated ... Platform Lifts . Previously the two standard colors were ... beautiful earth tone colors as standard colors at no additional ... the home but will enhance the beauty of the stairway. ... home color scheme or individual décor. , The new selection ...
(Date:7/11/2014)... (HealthDay News) -- People with the lowest incomes may have ... disease (PAD), a new study suggests. People with PAD ... limbs, most often the legs. The condition causes leg pain ... throughout the body. People with PAD have a higher risk ... nearly 6,800 people with PAD who took part in the ...
(Date:7/11/2014)... Volunteers from Scientology Churches ... week with drug education lectures, forums and conferences, information ... cities around the world. , Drug abuse is an ... Drug Abuse, abuse of alcohol and illicit drugs costs ... work, decreased productivity and healthcare. , In the ...
(Date:7/11/2014)... As part of its morcellator ... has been closely monitoring the ongoing meeting of ... Obstetrics and Gynecology Devices Panel, which has been ... risks associated with the use of power morcellators ... report published by Dow Jones Business News, a ...
Breaking Medicine News(10 mins):Health News:Argentina vs. Germany World Cup Finals Tickets & Brazil vs. Netherlands 3rd Place World Cup Tickets Are in Huge Demand 2Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2Health News:Poor More Prone to Leg Circulation Trouble 2Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4
... chair to support efforts to address the rising ... in Maryland BALTIMORE, April 10 Richard H. ... General (2002-2006) and President of the non-profit Canyon ... elected Chairman of the Pharmaceutical Research and Manufacturers ...
... scientific article is cited by other articles is currently the ... measure: the number of unique downloads. , A recent ... that downloads are a good predictor of citations and ... in an editorial by Journal of Vision (JOV) ...
... 14-17, 2009, Underwriters Laboratories Inc.,s (UL) Primary Designated ... Manager Jola Wroblewska will present International Electrotechnical Committee ... (IECEE) CB Test Laboratories and National Certification Bodies ... promote common application of the guidelines prepared by ...
... April 10 Rheumatoid arthritis (RA) is a systemic ... defense system attacks the joints through the thin layer ... the joints. The most visible symptoms of RA are ... and feet. It can cause fatigue, fever, loss of ...
... eye physicians recommends , sport-specific eyewear to prevent devastating ... what started out as a routine basketball game his senior ... was a young basketball star who played years of hoops ... the eye by a teammate, Stephen ended up with a ...
... for skin appearance in 3 trials , , THURSDAY, April 9 ... to improve the healing of skin scars, according to three ... administered to their skin before wounding and again 24 hours ... the way through the skin of the upper inner arm ...
Cached Medicine News:Health News:National Health Experts to Announce Creation of Bipartisan Coalition to Fight Maryland's Growing Burden of Chronic Disease Tuesday at Inner Harbor 2Health News:UL Medical Experts to Provide Instruction on Guidance for Risk Management in IEC 60601-1:2005 at IECEE Workshop 2Health News:Rheumatoid Arthritis Therapeutics in Taiwan 2Health News:Rheumatoid Arthritis Therapeutics in Taiwan 3Health News:Eye Protection is Essential for Texas Athletes 2Health News:Eye Protection is Essential for Texas Athletes 3Health News:Medication May Improve Scar Healing 2
They employ Lea Symbols. Contrast levels are the same at 25%, 10%, 5%, 2.5% and 1.25%. Each offers a different set of Lea Symbols to guard against memorization. Also uses recording forms (P/N 215400)...
Symbol 10' Test Chart 10/100 to 10/10 size. 9" x 14"....
Wilbrandt-binkhorst irrigating cannula....
Binkhorst, length 35 mm....
Medicine Products: